Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry

An independent study from Heart Rhythm Society’s (HRS) 2014 Annual Meeting comparing contemporary CRT-D longevity

DESCRIPTION

Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers was an independent, retrospective observational study comparing battery longevity of contemporary cardiac resynchronization therapy defibrillators (CRT-Ds) of all patients implanted with CRT-ICDs from January 1, 2007, to October 31, 2013, in Denmark.1

IMPORTANT OUTCOMES

• The four-year device battery survival rate was 81.1% for Medtronic, 95.8% for Biotronik, 95.7% for Boston Scientific, and 93.6% for St. Jude Medical
• Battery depletion or failure was identified in 43 (6.7%) Medtronic, 4 (1.1%) Biotronik, 1 (0.7%) Boston Scientific, and 33 (2.1%) St. Jude Medical CRT-D devices
• Battery depletion was indication for exchange of 71/81 (88%) devices
• The longevity of Medtronic CRT-Ds was significantly shorter (P<0.05) compared to other manufacturers

This study agreed with the results of Dr. Saba’s study2 — Boston Scientific CRT-Ds are lasting significantly longer than Medtronic CRT-Ds.3

Get the facts and cut the risk.

Boston Scientific offers ICDs and CRT-Ds designed to be the world’s longest lasting — with up to 80% more battery capacity than other available models.4 Better CRT-D longevity could mean a reduced risk of exposure to complications and infections for your patients.5,6,7

For more information, visit www.devicelongevity.com.
Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry

An independent study from the HRS 2014 Annual Meeting comparing contemporary CRT-D longevity

PATIENT COHORT

Study cohort included all patients (N=2,793) implanted with a CRT-D in Denmark from 2007 until October 31, 2013, as found in the Danish ICD Registry (DIR). Medtronic (N=651), Biotronik (N=369), Boston Scientific (N=136), and St Jude Medical (N=1,587).

METHODS

Patients were censored in case of device removal caused by other indications or patient death. Device longevity was compared between manufacturers with survival statistics using Kaplan Meier Plot.

PRIMARY ENDPOINTS

• Time to exchange of the device because of battery depletion
• Time to exchange of the device because of device failure

PRINCIPAL INVESTIGATOR

Jens B. Johansen, M.D., of Odense University Hospital, Odense, Denmark

1. Hjortshøj S, Johansen J, Jorgensen O, Nielsen J, Petersen H. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers: Data from the Danish ICD Registry. Presented at HRS 2014. http://ondemand.fhsonline.org/common/presentation-detail.aspx?19391/24139001. Device Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators Differs Between Manufacturers was an independent, retrospective observational study comparing battery longevity of contemporary cardiac resynchronization therapy defibrillators (CRT-Ds) of all patients implanted with CRT-ICDs from January 1, 2007, to October 31, 2013, in Denmark. The initial study population included 2,793 patients: battery depletion or device failure was identified in 43 Medtronic, 4 Biotronik, 1 Boston Scientific, and 33 St. Jude devices. Medtronic = 651 patients, Boston Scientific = 136 patients, St. Jude = 1,587 patients, Biotronik = 369 patients.

2. Alam MB, Munn Ib, Rattan R, Flanagan S, Adelstein E, Jan S, Saba S. Battery Longevity In Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators. Europace 2014; 16: 246-251. Kaplan Meier curves depicting survival of CRT devices free from battery depletion by device manufacturer. Battery Longevity in Cardiac Resynchronization Therapy Implantable Cardioverter Defibrillators is an independent, single-center, retrospective observational study comparing battery longevity of contemporary cardiac resynchronization therapy defibrillators (CRT-Ds) of all patients implanted with CRT-ICDs from January 1, 2008, to December 31, 2010, at University of Pittsburgh Medical Center hospitals. The initial study population included 746 patients: 94 were excluded at the onset because they were lost to follow-up within a month of implant, 6 others were excluded because they had a Biotronik CRT-D and that number of devices precludes meaningful comparison. Medtronic = 416 patients, Boston Scientific = 173 patients, St. Jude = 67 patients. Survival rate calculated using device replacements for battery depletion as indicated by ERI.

3. Time to exchange of the device because of battery depletion or device failure recorded in the Danish ICD Registry was the endpoint.


Potential Adverse Events

Potential adverse events from implantation of the CRT-D system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematomas/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of device failure, or imagined shocking. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. (Rev. S)

CRT-D Systems from Boston Scientific – PUNCTUA™, ENERGEN™, and INCEPTA™

Indications and Usage

The PUNCTUA™, ENERGEN™, and INCEPTA™ Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for patients with heart failure who receive stable optimal pharmacologic therapy (OPT) for heart failure and who meet any one of the following classifications:

- Moderate to severe heart failure (NYHA Class III-IV) with EF ≤ 35% and QRS duration ≥ 120 ms
- Left bundle branch block (LBBB) with QRS ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or nonischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure

Contraindications

There are no contraindications for this device.

Warnings

Read the product labeling thoroughly before implanting the pulse generator to avoid damage to the system. For single patient use only. Do not reuse, reprocess, or resterilize. Program the pulse generator Tachy Mode to Off during implant, explant or postmortem procedures. Always have external defibrillator protection available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel skilled in CPR are present during post-implant device testing. Advise patients to seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. Do not expose a patient to MRI scanning. Do not subject a patient with an implanted pulse generator to diaphyseal. Do not use atrial-tracking modes in patients with chronic refractory atrial tachyarhythmias. Do not use atrial-only modes in patients with heart failure. LV lead dislodgment to a position near the atria can result in atrial oversensing and LV pacing inhibition. Physicians should use medical discretion when implanting this device in patients who present with slow VT. Do not kink, twist or braid the lead with other leads. Do not use defibrillation patch leads with the CRT-D system. Do not use this pulse generator with another pulse generator. For Patient Triggered Monitor (PTM) feature, make sure the feature is enabled prior to sending the patient home with a magnet. Once the PTM feature has been triggered and the magnet response programming is set to inhibit therapy, the patient should not reaply the magnet. For DF4-LLHH or DF4-LLHO leads, use caution handling the lead terminal when the Connector Tool is not present on the lead and do not directly contact the lead terminal with any surgical instruments or electrical connections such as PSA (alligator) clips, ECG connections, forceps, hemostats, and clamps. Do not contact any other portion of the DF4-LLHH or DF4-LLHO lead terminal, other than the terminal pin even when the lead cap is in place.

Precautions

For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; follow-up testing; explant and disposal; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments; and supplemental precautionary information. Advise patients to avoid sources of electromagnetic interference (EMI) because EMI may cause the pulse generator to deliver inappropriate therapy or inhibit appropriate therapy.

Potential Adverse Events

Potential adverse events from implantation of the CRT-D system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematomas/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of device failure, or imagined shocking. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. (Rev. C)

ICD Systems from Boston Scientific – PUNCTUA™, ENERGEN™, and INCEPTA™

ICD Indications and Usage

PUNCTUA™, ENERGEN™, and INCEPTA™ ICDs are intended to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.

Contraindications

Use of these ICD systems are contraindicated in: Patients whose ventricular tachyarhythmias may have reversible cause, such as 1) digitalis intoxication, 2) electrolyte imbalance, 3) hypoxia, or 4) sepsis, or whose ventricular tachyarhythmias have a transient cause, such as 1) acute myocardial infarction, 2) electrocution, or 3) drowning. Patients who have a unipolar pacemaker.

Warnings

Read the product labeling thoroughly before implanting the pulse generator to avoid damage to the ICD system. For single patient use only. Do not reuse, reprocess, or resterilize. Program the pulse generator ventricular Tachy Mode to Off during implant, explant or postmortem procedures. Always have external defibrillator protection available during implant and electrophysiologic testing. Ensure that an external defibrillator and medical personnel skilled in CPR are present during post-implant device testing. Patients should seek medical guidance before entering environments that could adversely affect the operation of the active implantable medical device, including areas protected by a warning notice that prevents entry by patients who have a pulse generator. Do not expose a patient to MRI scanning. Do not subject a patient with an implanted pulse generator to diaphyseal. Do not use atrial-tracking modes in patients with chronic refractory atrial tachyarhythmias. Do not use atrial-only modes in patients with heart failure. LV lead dislodgment to a position near the atria can result in atrial oversensing and LV pacing inhibition. Physicians should use medical discretion when implanting this device in patients who present with slow VT. Do not kink, twist or braid the lead with other leads. Do not use defibrillation patch leads with the CRT-D system. Do not use this pulse generator with another pulse generator. For Patient Triggered Monitor (PTM) feature, make sure the feature is enabled prior to sending the patient home with a magnet. Once the PTM feature has been triggered and the magnet response programming is set to inhibit therapy, the patient should not reaply the magnet. For DF4-LLHH or DF4-LLHO leads, use caution handling the lead terminal when the Connector Tool is not present on the lead and do not directly contact the lead terminal with any surgical instruments or electrical connections such as PSA (alligator) clips, ECG connections, forceps, hemostats, and clamps. Do not contact any other portion of the DF4-LLHH or DF4-LLHO lead terminal, other than the terminal pin even when the lead cap is in place.

Precautions

For specific information on precautions, refer to the following sections of the product labeling: clinical considerations; sterilization and storage; implantation; device programming; follow-up testing; explant and disposal; environmental and medical therapy hazards; hospital and medical environments; home and occupational environments; and supplemental precautionary information. Advise patients to avoid sources of electromagnetic interference (EMI).

Potential Adverse Events

Potential adverse events from implantation of the ICD system include, but are not limited to, the following: allergic/physical/physiologic reaction, death, erosion/migration, fibrillation or other arrhythmias, lead or accessory breakage (fracture/insulation/lead tip), hematomas/seroma, inappropriate or inability to provide therapy (shocks/pacing/sensing), infection, procedure related, and component failure. Patients may develop psychological intolerance to a pulse generator system and may experience fear of shocking, fear of device failure, or imagined shocking. In rare cases severe complications or device failures can occur.

Refer to the product labeling for specific indications, contraindications, warnings/precautions and adverse events. Rx only. (Rev. C)

CRM-274920-AB MAY2016